Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

10.80 -0.53 (-4.63%)
Streaming Delayed Price Updated: 2:51 PM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 536,301
Open 11.24
Bid (Size) 10.80 (700)
Ask (Size) 10.81 (400)
Prev. Close 11.33
Today's Range 10.77 - 11.24
52wk Range 5.450 - 12.49
Shares Outstanding 68,438,576
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript ↗
Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
Kura Oncology Q1 Earnings Call Highlights ↗
Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad... 
Via MarketBeat
Topics Earnings

Performance

YTD
+4.5%
+4.5%
1 Month
+13.3%
+13.3%
3 Month
+19.4%
+19.4%
6 Month
+15.4%
+15.4%
1 Year
+76.3%
+76.3%

More News

Read More
Kura Oncology (NASDAQ:KURA) Slips After Q1 Earnings Miss ↗
Via Chartmill
News headline image
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
From Kura Oncology, Inc.
Via GlobeNewswire
News headline image
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
From Kura Oncology, Inc.
Via GlobeNewswire
KURA ONCOLOGY INC (NASDAQ:KURA) Posts Q4 Revenue Beat but EPS Miss, Stock Falls in Pre-Market ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
From Kura Oncology, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Kura Scores A Big Win As FDA Approves Its New Leukemia Pill ↗
Via Benzinga
News headline image
Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients ↗
Via Stocktwits
News headline image
Tech's AI Surge Meets Pharma's Resilient Recovery: A Tale of Two Markets in Late 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Kura Oncology (NASDAQ:KURA) Reports Q3 2025 Revenue Miss But Narrower-Than-Expected Loss ↗
Via Chartmill
News headline image
Earnings Scheduled For May 1, 2025 ↗
Via Benzinga
News headline image
Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial ↗
Via Benzinga
News headline image
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Via MarketMinute
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗
Via Benzinga
News headline image
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
Kura (KURA) Revenue Drops 61% ↗
Via The Motley Fool

Frequently Asked Questions

Is Kura Oncology, Inc. - Common Stock publicly traded?
Yes, Kura Oncology, Inc. - Common Stock is publicly traded.
What exchange does Kura Oncology, Inc. - Common Stock trade on?
Kura Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kura Oncology, Inc. - Common Stock?
The ticker symbol for Kura Oncology, Inc. - Common Stock is KURA on the Nasdaq Stock Market
What is the current price of Kura Oncology, Inc. - Common Stock?
The current price of Kura Oncology, Inc. - Common Stock is 10.80
When was Kura Oncology, Inc. - Common Stock last traded?
The last trade of Kura Oncology, Inc. - Common Stock was at 07/16/26 02:51 PM ET
What is the market capitalization of Kura Oncology, Inc. - Common Stock?
The market capitalization of Kura Oncology, Inc. - Common Stock is 739.48M
How many shares of Kura Oncology, Inc. - Common Stock are outstanding?
Kura Oncology, Inc. - Common Stock has 739M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.